Literature DB >> 32862141

Structure, function, and inhibitor targeting of HIV-1 Nef-effector kinase complexes.

Ryan P Staudt1, John J Alvarado1, Lori A Emert-Sedlak1, Haibin Shi1, Sherry T Shu1, Thomas E Wales2, John R Engen2, Thomas E Smithgall3.   

Abstract

Antiretroviral therapy has revolutionized the treatment of AIDS, turning a deadly disease into a manageable chronic condition. Life-long treatment is required because existing drugs do not eradicate HIV-infected cells. The emergence of drug-resistant viral strains and uncertain vaccine prospects highlight the pressing need for new therapeutic approaches with the potential to clear the virus. The HIV-1 accessory protein Nef is essential for viral pathogenesis, making it a promising target for antiretroviral drug discovery. Nef enhances viral replication and promotes immune escape of HIV-infected cells but lacks intrinsic enzymatic activity. Instead, Nef works through diverse interactions with host cell proteins primarily related to kinase signaling pathways and endosomal trafficking. This review emphasizes the structure, function, and biological relevance of Nef interactions with host cell protein-tyrosine kinases in the broader context of Nef functions related to enhancement of the viral life cycle and immune escape. Drug discovery targeting Nef-mediated kinase activation has allowed identification of promising inhibitors of multiple Nef functions. Pharmacological inhibitors of Nef-induced MHC-I down-regulation restore the adaptive immune response to HIV-infected cells in vitro and have the potential to enhance immune recognition of latent viral reservoirs as part of a strategy for HIV clearance.
© 2020 Staudt et al.

Entities:  

Keywords:  AIDS; Btk; CD4; HIV-1 Nef; Hck; Itk; MHC-I; SH2 domain; SH3 domain; Src homology 2 domain (SH2 domain); Src homology 3 domain (SH3 domain); Src-family kinases; Tec-family kinases; bimolecular fluorescence complementation (BiFC); dimerization; endocytosis; human immunodeficiency virus (HIV); infectious disease; major histocompatibility complex (MHC); protein-protein interaction

Mesh:

Substances:

Year:  2020        PMID: 32862141      PMCID: PMC7606690          DOI: 10.1074/jbc.REV120.012317

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  106 in total

Review 1.  Key Principles of Antiretroviral Pharmacology.

Authors:  Brandon Dionne
Journal:  Infect Dis Clin North Am       Date:  2019-09       Impact factor: 5.982

Review 2.  HIV-1 Nef: Taking Control of Protein Trafficking.

Authors:  Estela A Pereira; Luis L P daSilva
Journal:  Traffic       Date:  2016-06-03       Impact factor: 6.215

3.  HIV-1 Nef disrupts antigen presentation early in the secretory pathway.

Authors:  Matthew R Kasper; Jeremiah F Roeth; Maya Williams; Tracey M Filzen; Rebekah I Fleis; Kathleen L Collins
Journal:  J Biol Chem       Date:  2005-01-14       Impact factor: 5.157

4.  Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene.

Authors:  M Y Chowers; C A Spina; T J Kwoh; N J Fitch; D D Richman; J C Guatelli
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

5.  Downregulation of CD4 by human immunodeficiency virus type 1 Nef is dependent on clathrin and involves direct interaction of Nef with the AP2 clathrin adaptor.

Authors:  Rittik Chaudhuri; O Wolf Lindwasser; William J Smith; James H Hurley; Juan S Bonifacino
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

6.  Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity.

Authors:  Lori A Emert-Sedlak; Purushottam Narute; Sherry T Shu; Jerrod A Poe; Haibin Shi; Naveena Yanamala; John Jeff Alvarado; John S Lazo; Joanne I Yeh; Paul A Johnston; Thomas E Smithgall
Journal:  Chem Biol       Date:  2013-01-24

7.  Selective targeting of ITK blocks multiple steps of HIV replication.

Authors:  Julie A Readinger; Gillian M Schiralli; Jian-Kang Jiang; Craig J Thomas; Avery August; Andrew J Henderson; Pamela L Schwartzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-28       Impact factor: 11.205

8.  HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation.

Authors:  Annachiara Rosa; Ajit Chande; Serena Ziglio; Veronica De Sanctis; Roberto Bertorelli; Shih Lin Goh; Sean M McCauley; Anetta Nowosielska; Stylianos E Antonarakis; Jeremy Luban; Federico Andrea Santoni; Massimo Pizzato
Journal:  Nature       Date:  2015-09-30       Impact factor: 49.962

9.  CSF-induced and HIV-1-mediated distinct regulation of Hck and C/EBPbeta represent a heterogeneous susceptibility of monocyte-derived macrophages to M-tropic HIV-1 infection.

Authors:  Iwao Komuro; Yasuko Yokota; Sachiko Yasuda; Aikichi Iwamoto; Kiyoko S Kagawa
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307

10.  HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2.

Authors:  Tram N Q Pham; Sabelo Lukhele; Fadi Hajjar; Jean-Pierre Routy; Éric A Cohen
Journal:  Retrovirology       Date:  2014-02-06       Impact factor: 4.602

View more
  8 in total

Review 1.  Role of the receptor for activated C kinase 1 during viral infection.

Authors:  Yan Wang; Xiaorong Qiao; Yuhan Li; Qingru Yang; Lulu Wang; Xiaolan Liu; Hua Wang; Hongxing Shen
Journal:  Arch Virol       Date:  2022-06-28       Impact factor: 2.685

2.  Lentiviral Nef Proteins Differentially Govern the Establishment of Viral Latency.

Authors:  Eric Carlin; Braxton Greer; Kelsey Lowman; Alexander G Dalecki; Alexandra Duverger; Frederic Wagner; Olaf Kutsch
Journal:  J Virol       Date:  2022-03-10       Impact factor: 6.549

3.  Inhibitors of HIV-1 Nef-Mediated Activation of the Myeloid Src-Family Kinase Hck Block HIV-1 Replication in Macrophages and Disrupt MHC-I Downregulation.

Authors:  Lori A Emert-Sedlak; Omar Moukha-Chafiq; Haibin Shi; Shoucheng Du; John J Alvarado; Vibha Pathak; Samuel G Tanner; Robert N Hunter; Miranda Nebane; Li Chen; Tatiana V Ilina; Rieko Ishima; Sixue Zhang; Yury V Kuzmichev; Elizabeth R Wonderlich; Susan M Schader; Corinne E Augelli-Szafran; Roger G Ptak; Thomas E Smithgall
Journal:  ACS Infect Dis       Date:  2022-01-05       Impact factor: 5.578

Review 4.  HIV-1 restriction by SERINC5.

Authors:  Lucía Cano-Ortiz; Tom Luedde; Carsten Münk
Journal:  Med Microbiol Immunol       Date:  2022-03-25       Impact factor: 3.402

5.  Visualization of Host Cell Kinase Activation by Viral Proteins Using GFP Fluorescence Complementation and Immunofluorescence Microscopy.

Authors:  Sherry T Shu; Wing Fai Li; Thomas E Smithgall
Journal:  Bio Protoc       Date:  2021-07-05

6.  Immune subversion by HIV: part B.

Authors:  Christophe Vanpouille; Leonid Margolis
Journal:  EMBO J       Date:  2020-12-08       Impact factor: 14.012

7.  Evolutionary plasticity of SH3 domain binding by Nef proteins of the HIV-1/SIVcpz lentiviral lineage.

Authors:  Zhe Zhao; Riku Fagerlund; Helena Tossavainen; Kristina Hopfensperger; Rishikesh Lotke; Smitha Srinivasachar Badarinarayan; Frank Kirchhoff; Perttu Permi; Kei Sato; Daniel Sauter; Kalle Saksela
Journal:  PLoS Pathog       Date:  2021-11-15       Impact factor: 6.823

Review 8.  Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor.

Authors:  Lori A Emert-Sedlak; Haibin Shi; Colin M Tice; Li Chen; John J Alvarado; Sherry T Shu; Shoucheng Du; Catherine E Thomas; Jay E Wrobel; Allen B Reitz; Thomas E Smithgall
Journal:  Viruses       Date:  2022-09-13       Impact factor: 5.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.